A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This study is a dose block-randomized, double-blind, placebo-controlled, single- and
multiple-ascending dose study. For each dose group, 6 subjects will be randomly assigned to
the test group (TB-840) and 2 subjects will be randomly assigned to the control group
(placebo). Adverse event (AE) monitoring, physical examination, vital signs, ECG, clinical
laboratory test will be done for safety and tolerability assessment, and blood and urine
samples will be collected for Pharmacokinetic (PK) assessment.